arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

CASTLE BIOSCIENCES INC

CSTL
$34.09 ▼ -1.72 (-4.80%) at close
Healthcare ·Services-Medical Laboratories ·USServices-Medical Laboratories
35 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
34
Health
Poor
Moderately Bearish
auto_awesome

Analytical Summary

CASTLE BIOSCIENCES INC faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). Investors should exercise caution and monitor for improvement in key metrics.

Market Cap $1.0B
Dividend Yield —
Revenue Growth 20.1% ↗
Op. Margin -3.0% ↗
ROIC -0.5% ↗
FCF / Share $0.22 ↗
Trailing P/E —
Price / Book 2.2x
FCF Yield 0.6%
Debt / Equity 0.02
info Valuation on last close. End-of-day price, Nov 5, 2026.

35-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$103.55M
↑ +20.1% —
Net Income Profit after all expenses
$-14.52M
↑ +43.8% —
Operating Margin Operating profit as % of sales
-3.0%
↑ +86.5% 13th
FCF / Share Free cash flow per share
$0.22
↑ +118.6% —
Long-Term Debt Long-term obligations
$10.07M
— +0.1% —
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability ↑
29
Returns ↑
38
Financial Health →
48
Cash Quality
9

Dividend History

Dividend / share · sourced from SEC filings
$0.00 Latest / share

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 9 years · 35 quarters